膜杰作
Star Staining
描述（Description）
HEK293/Human Anti-CD19 Stable Cell Line
应用说明（Application）
Binding assay by FACS and cell based ELISA
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (5 μg/mL)
培养基（Culture Medium）
DMEM medium + 10% FBS
冻存液（Freeze Medium）
10% DMSO + 90% FBS
装量（Quantity）
1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Receptor Assay
FACS assay shows that PE-Labeled Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1 can bind to HEK293/Human Anti-CD19 Stable Cell Line. HEK293/Human Anti-CD19 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).
Protocol
FACS assay shows that PE-Labeled Human CD19 (20-291), His Tag can bind to HEK293/Human Anti-CD19 Stable Cell Line. HEK293/Human Anti-CD19 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).
Protocol
如有相关细胞池需求请联系我们
背景（Background）
Chimeric antigen receptors (CARs) comprise interact domains, of which target cancer cell expressed antigens and allow T cell to efficiently kill the cancer cell. FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. Our CAR-like cells apply the HEK293 cells for the expression of FMC63 which will be presented on the cell membrane. It mimics the real CAR-T cell reaction and it is used as positive control for Anti-CD19 scFv Antibody flow cytometry detection.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
